New 2025 Data Sheds Light on 340B Activity in Georgia
Pioneer Institute has released updated #340B state fact sheets for 2025
The Pioneer Institute has released updated 340B State Fact Sheets for 2025, offering a detailed look into how the 340B Drug Pricing Program is operating in each state—including Georgia. The findings raise key questions about equity, oversight, and impact on low-income communities.
In Georgia:
- 30% of the state’s 340B contract pharmacies are located outside of Georgia, including some as far away as Hawaii.
- 43% of contract pharmacies intended to serve low-income Georgians are actually located in affluent neighborhoods.
- Some hospitals, such as Northside Hospital and AU Medical Center, operate dozens of contract pharmacies—many out of state—while others serve patients effectively with far fewer.
- PBM-owned and chain pharmacies dominate the list of top 340B contract pharmacies in Georgia.
- Despite these concerns, Georgia 340B hospitals reported above-average charity care: 4.92% of operating expenses compared to the national average of 2.15%.
The data also explores:
- Which hospitals have the most (and most out-of-state) contract pharmacies
- How charity care levels vary between insured and uninsured patients
- The correlation between hospital wealth and charitable contributions
➡️ View Georgia’s full 2025 fact sheet and explore national comparisons: https://pioneerinstitute.org/340babuse/340b-state-fact-sheets
As policymakers continue to examine the effectiveness and transparency of the 340B program, this report highlights the importance of tracking how resources intended for underserved populations are actually being deployed.
New coalition forms to develop a national innovation roadmap to strengthen and extend America’s global leadership in biotechnology
BioMADE Announces $21.4 Million Invested in 14 Projects to Develop the U.S. Bioindustrial Manufacturing Industry and Advance National Security Priorities
April 17, 2026 - Nutrivert Inc., a developer of non-antibiotic replacements for antibiotic growth promoters in livestock, today announced it has completed the first close, raising $2.375 million, of its Series A-2 funding round of $6 million. The round was led by global animal health investor Arrow Ventures with participation from other investors. The funding will be used to further develop Nutrivert’s manufacturing, human food safety and target animal safety and efficacy packages for the company’s lead product Nutrivert LDPP. Nutrivert LDPP is a proprietary, novel, orally available, lipidated synthetic enantiomeric desmuramyl analog of muramyl dipeptide, the smallest conserved immunoactive component of bacterial peptidoglycan. LDPP has no antibacterial effect but has consistently promoted growth and improved feed efficiency in pig studies. LDPP binds to the mammalian NOD2 receptor and is the only NOD2 ligand reported to inhibit the inflammatory signal NF-κB. In pilot studies, LDPP rescued 70kg pigs from an otherwise lethal dose of porcine reproductive and respiratory syndrome virus (PRRSV) and abrogated influenza disease symptoms in piglets. The Company intends to develop LDPP for all major livestock species worldwide. Patents have been granted in most major markets. The global antibiotic growth promoter market is worth an estimated $5.8 billion. Approximately 73% of all antibiotics are fed to livestock. The market is believed to be the world’s largest drug market by volume, with ~100,000 tons of active pharmaceutical ingredient administered annually. FDA’s latest data, for 2024, show a 13% rise in U.S. livestock antibiotic use since 2017. The Food and Agriculture Organization reports that livestock antibiotics are mostly given to speed animal growth. Regulators and non-governmental organizations have called for reduction of antibiotic use in livestock, citing concerns that the global, intensive use of antibiotics, often at subtherapeutic doses, selects for antimicrobial resistance: bacteria that are “immune” to antibiotics and that therefore pose a threat to public health. Spillovers of antibiotic-resistant bacteria from livestock to humans have been documented. “Nutrivert LDPP has consistently improved feed efficiency in pigs without antibiotics,” said Bernhard Kaltenboeck, CSO. “We are excited to have the support of Arrow Ventures and our other investors in bringing a new tool that will help producers reduce production costs and reduce selection pressure for antimicrobial resistance.” About Nutrivert LDPP: LDPP is an investigational compound currently undergoing clinical evaluation. It has not been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other global regulatory authority for any indication. The safety and efficacy of LDPP have not been established. Any mention of potential use is based on preliminary data and does not guarantee future regulatory clearance or commercial availability.
